humanitarian
Translated · Українська · 2–5m lag
Звіт з питань людських ліків (EPAR): Spevigo, sesolimbab, Date of Permissionation: 09/12/2022, consution: 6, Status: Authorized
Звіт про людські ліки (EPAR): fesgo, peruzumab, trastuzuba, Date of Pentration: 21/12/2020, version: 8, Status: Authorized
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
12 reports · 2 sources
EMA What Is NewЗвіт з питань людських ліків (EPAR): Spevigo, sesolimbab, Date of Permissionation: 09/12/2022, consution: 6, Status: AuthorizedEMA What Is NewЗвіт з питань людських ліків (EPAR): Spevigo, sesolimbab, Date of Permissionation: 09/12/2022, consution: 6, Status: AuthorizedEMA What Is NewЗвіт про лікування людських ліків (EPAR): KemSu, sufentanil,ketamin, status: відмовленоEMA What Is NewHuman medicines European public assessment report (EPAR): Meplyffa, arimoclomol, Status: RefusedEMA What Is NewЗвіт про лікування людських ліків (EPAR): Ruxolinitib Krka, rexolitinib, status: cysEMA What Is NewHuman medicines European public assessment report (EPAR): Donrafylix, insulin aspart, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Zybrivo, sintilimab, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Fondaparinux sodium Evumed, fondaparinux sodium, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Amlypave, anselamimab, Status: Application withdrawnEMA What Is NewHuman medicines European public assessment report (EPAR): Baxfendy, baxdrostat, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Garzulys, insulin aspart, Status: OpinionEMA What Is NewЗвіт про лікування людських ліків (EPAR): KemSu, sufentanil,ketamin, status: відмовлено4 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources